ICCCHIGH SIGNALFINANCIAL10-K

ICCC delivered exceptional financial performance with revenue surging 51.6% to $26.5M and net loss improving dramatically from -$2.2M to -$1.0M, marking a strong turnaround.

The company achieved significant operational leverage with gross profit growing 44.1% while simultaneously reducing R&D expenses by 22%, demonstrating improved operational efficiency. The substantial revenue growth combined with disciplined cost management and debt reduction of 11.1% suggests the business has reached an inflection point toward profitability.

Comparing 2026-03-30 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

ICCC experienced transformational financial improvement across virtually all metrics, with revenue jumping 51.6% to $26.5M driving gross profit growth of 44.1% to $11.4M. The company demonstrated strong cost discipline by reducing R&D expenses 22% and total debt by 11.1%, while net losses improved dramatically by 51.8% from -$2.2M to -$1.0M. The combination of exceptional top-line growth, expanding margins, deleveraging, and rapid progress toward profitability signals a fundamental business turnaround that should attract significant investor attention.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+51.8%
-$2.2M-$1.0M

Net income grew 51.8% — bottom-line growth signals improving overall business health.

Revenue
P&L
+51.6%
$17.5M$26.5M

Strong top-line growth of 51.6% — accelerating demand or successful expansion into new markets.

Gross Profit
P&L
+44.1%
$7.9M$11.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Interest Expense
P&L
+36.5%
$349K$476K

Interest expense surged 36.5% — significant debt increase or rising rates materially impacting earnings.

Inventory
Balance Sheet
+30.3%
$7.1M$9.3M

Inventory surged 30.3% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

R&D Expense
P&L
-22%
$3.9M$3.0M

R&D spending cut 22% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
+12.6%
$15.0M$16.9M

Current assets grew 12.6% — improving short-term liquidity or inventory/receivables build.

Total Liabilities
Balance Sheet
-12%
$17.6M$15.5M

Liabilities reduced 12% — deleveraging improves balance sheet strength and financial flexibility.

Total Debt
Balance Sheet
-11.1%
$10.2M$9.1M

Debt reduced 11.1% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-28
ADDED
iccc20251231_10k.htm 0000811641 ImmuCell Corporation false --12-31 FY 2025 true true true false Our Board of Directors has overall oversight responsibility with respect to our approach to risk management, including risks relating to cybersecurity.
Although the Board of Directors has the ultimate responsibility for risk oversight, our management team, including our President and CEO, has operational responsibility for cybersecurity matters, including the day-to-day management of our cybersecurity risks, and oversees processes for the prevention, detection, mitigation and remediation of any cybersecurity incidents.
While our management team does not have cybersecurity expertise, we coordinate with expert consultants to assess and manage risks.
Our Board of Directors reviews cybersecurity threats and risk controls based on information provided by management and outside consultants.
Our Board of Directors has overall oversight responsibility with respect to our approach to risk management, including risks relating to cybersecurity.
+7 more — sign up free →
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
1 ImmuCell Corporation OUTLINE TO ITEM 1 BUSINESS: - Summary - Production Capacity Increase and Product Contamination - Animal Health Products - Sales and Markets - Product Development - Competition - Intellectual Property - Government Regulation - Employees - Public Information Summary ImmuCell Corporation was founded in 1982 and completed an initial public offering of common stock in 1987.
After achieving approval from the Center for Veterinary Biologics, U.S.
Department of Agriculture (USDA) to sell First Defense in 1991, we focused most of our efforts during the 1990 s on attempting to develop human product applications of the underlying milk protein purification technology.
Beginning in 1999, we re-focused our business strategy on the First Defense product line.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →